Triapine

Phase 3Small molecule

Triapine is a small molecule that works as a Ribonucleotide Reductase Inhibitor.[2] It is being investigated across 22 indications, with its most advanced program in Phase 3.[1]

Triapine is one of 514 small molecule programs targeting Kidney Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

513

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Nervous System InjuryActive, not recruiting

LymphomaActive, not recruiting

Gallbladder CancerActive, not recruiting

AdenocarcinomaActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Endometrial Serous AdenocarcinomaActive, not recruiting

Uterine CancerActive, not recruiting

Chronic Myelomonocytic LeukemiaActive, not recruiting

Neuroendocrine NeoplasmActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Nervous System InjuryPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Gallbladder CancerPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Alzheimer DiseasePhase 3

Active, not recruiting

Endometrial Serous AdenocarcinomaPhase 1

Active, not recruiting

Uterine CancerPhase 1

Active, not recruiting

Chronic Myelomonocytic LeukemiaPhase 2

Active, not recruiting

Neuroendocrine NeoplasmPhase 2

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Triapine

VVion Pharmaceuticals

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Tykerb

GSK

Preclinical

80 4

Halaven

Eisai

Preclinical

38 5

Tecentriq

Roche

Preclinical

36 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Metastatic Neuroendocrine Tumor

NCT05724108

Q2 2027

Phase 1Recruiting

Astrocytoma, IDH-Mutant, Grade 2

NCT06860594

Q2 2030

Phase 1Active, not recruiting

Glioblastoma

NCT06410248

Clinical

Trials by Indication[1]

Pancreatic Cancer3 trials

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00064051

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00078975·26 enrolled

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00288093·30 enrolled

Non-Small Cell Lung Cancer3 trials

A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00077350·48 enrolled

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Completed·CCancer Therapeutics Research Group·Phase 2·NCT00077415·31 enrolled

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00064064

Advanced Cancer2 trials

3-AP in Treating Patients With Advanced Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00006218

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00024323

Radiation Therapy2 trials

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00335998·24 enrolled

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02595879·21 enrolled

Glioblastoma1 trial

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Active, not recruiting·NNorthwestern University·Phase 1·NCT06410248·30 enrolled

23 more indications

Hematologic Cancer1 trial

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00064090

Cancer of the Pancreas1 trial

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00085371·116 enrolled

Advanced Hematologic Malignancies1 trial

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00077181·48 enrolled

Breast Cancer1 trial

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00095888·68 enrolled

Patients With Solid Tumors1 trial

3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors

Completed·VVion Pharmaceuticals·Phase 1·NCT00004213

Uterine Cancer1 trial

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04494113·12 enrolled

Unresectable Solid Tumor1 trial

Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00084877·36 enrolled

Chronic Myelomonocytic Leukemia1 trial

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00381550·35 enrolled

Renal Cell Carcinoma1 trial

3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00075660·19 enrolled

Advanced or Metastatic Solid Tumors1 trial

3-AP in Treating Patients With Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00390052·24 enrolled

Myelodysplastic Syndrome1 trial

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00077558

Adenocarcinoma1 trial

3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00077545·39 enrolled

Lymphoma1 trial

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00293345·30 enrolled

Metastatic Cancer1 trial

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

Completed·VVion Pharmaceuticals·Phase 1·NCT00016874

Gallbladder Cancer1 trial

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00075504·33 enrolled

Cervical Cancer1 trial

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00941070·26 enrolled

Prostate Cancer1 trial

3-AP in Treating Patients With Advanced Prostate Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00054015

Primary Peritoneal Cancer1 trial

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00081276·48 enrolled

Neuroendocrine Tumors1 trial

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04234568·31 enrolled

Refractory Solid Tumors1 trial

3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079014·36 enrolled

Metastatic Neuroendocrine Tumor1 trial

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05724108·94 enrolled

Advanced Vaginal Adenocarcinoma1 trial

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02466971·450 enrolled

Astrocytoma, IDH-Mutant, Grade 21 trial

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06860594·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Triapine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triapine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triapine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vion Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Ribonucleotide Reductase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVion Pharmaceuticals

Triapine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q2 2030

Trials by Indication[1]

Pancreatic Cancer3 trials

Non-Small Cell Lung Cancer3 trials

Advanced Cancer2 trials

Radiation Therapy2 trials

Glioblastoma1 trial

Hematologic Cancer1 trial

Cancer of the Pancreas1 trial

Advanced Hematologic Malignancies1 trial

Breast Cancer1 trial

Patients With Solid Tumors1 trial

Uterine Cancer1 trial

Unresectable Solid Tumor1 trial

Chronic Myelomonocytic Leukemia1 trial

Renal Cell Carcinoma1 trial

Advanced or Metastatic Solid Tumors1 trial

Myelodysplastic Syndrome1 trial

Adenocarcinoma1 trial

Lymphoma1 trial

Metastatic Cancer1 trial

Gallbladder Cancer1 trial

Cervical Cancer1 trial

Prostate Cancer1 trial

Primary Peritoneal Cancer1 trial

Neuroendocrine Tumors1 trial

Refractory Solid Tumors1 trial

Metastatic Neuroendocrine Tumor1 trial

Advanced Vaginal Adenocarcinoma1 trial

Astrocytoma, IDH-Mutant, Grade 21 trial

References

Drug Info

Quick Facts

Related News